Previous 10 | Next 10 |
2023-03-22 17:06:31 ET An FDA advisory panel voted 9-0 that the data on Biogen ( NASDAQ: BIIB ) and Ionis Pharmaceuticals ( IONS ) amyotrophic lateral sclerosis (ALS) drug tofersen likely predicts it benefit. The recommendation from the Peripheral and Central...
2023-03-13 23:58:45 ET Summary Silence Therapeutics is an underfollowed British siRNA company focusing on cardiovascular and autoimmune diseases. Silence Therapeutics is a de-risked investment opportunity with significant potential upside, supported by its robust pipeline, strateg...
Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) PR Newswire 35-week data included in the filing demonstrated a statistically significant and clinically meaningful ...
Summary Merck is an American biopharma powerhouse that has generated consistent compounding growth, increasing its top line and EPS. Merck expects to deploy capital through strategic small bolt-on acquisitions, which we are a big fan of, rather than rampant big indiscriminate acquisitio...
Summary We maintain a buy rating on Royalty Pharma. Royalty Pharma recently reported positive FY 2022 earnings. Adjusted cash receipts, adjusted EBITDA, and adjusted cash flow surged by 10%, 10%, and 15%, respectively, before an accelerated Biohaven redemption payment. We like R...
Ionis Pharmaceuticals, Inc. (IONS) Q4 2022 Results Conference Call February 22, 2023 11:30 AM ET Company Participants Wade Walke - SVP, IR Brett Monia - CEO Beth Hougen - CFO Eugene Schneider - Chief Clinical Development Officer Onaiza Cadoret - Chief Global Pr...
Summary BioCryst's main value driver, ORLADEYO, is already profitable in its second year on the market and generated over $250 million in revenue in 2022. ORLADEYO is successfully differentiating itself in a multi-billion dollar market and is on track to achieve blockbuster status in a ...
Ionis Pharmaceuticals press release ( NASDAQ: IONS ): Q4 net loss of $168M Revenue of $152M (-65.5% Y/Y) misses by $8.21M . FY23 Guidance: Revenue of greater than $575M Net operating loss on a non-GAAP basis <$425M Cash, cash equivalents and short-term investmen...
Ionis reports fourth quarter and full year 2022 financial results PR Newswire Eplontersen NDA submitted to FDA; tofersen under regulatory review for marketing approval in U.S. and EU Phase 3 data planned for eplontersen and olezarsen; robust late-stage pipeline expandi...
Ionis Pharmaceuticals ( NASDAQ: IONS ) is scheduled to announce Q4 earnings results on Wednesday, February 22nd, before market open. The consensus EPS Estimate is -$0.86 (-161.0% Y/Y) and the consensus Revenue Estimate is $160.21M (-63.6% Y/Y). Over the last 1 year, IONS has...
News, Short Squeeze, Breakout and More Instantly...
Ionis Pharmaceuticals Inc. Company Name:
IONS Stock Symbol:
NASDAQ Market:
Ionis Pharmaceuticals Inc. Website:
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome PR Newswire ION582 showed robust and consistent benefit in communication, cognition and motor function in a broad patient population evaluated with a comprehensive set o...
Ionis to hold second quarter 2024 financial results webcast PR Newswire Webcast scheduled for Thursday, August 1 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , July 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced ...
Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease PR Newswire Zilganersen is the first investigational medicine in clinical development for people with Alexander disease, a rare, life-threatening neurological condition...